Fabry Disease

  • Alessandro P. Burlina
  • Juan Politei


Fabry disease (FD, OMIM 301500) is a progressive inborn error of metabolism with important roles being played by cellular dysfunction and microvascular pathology induced by lysosomal glycosphingolipid deposition. Absent or deficient activity of lysosomal exoglycohydrolase alpha galactosidase A (a-Gal A) results in progressive accumulation of globotriaosylceramide (Gb3 or GL3; also known as ceramidetrihexoside or CTH) and related glycosphingolipids (galabiosylceramide) within lysosomes which are ubiquitous subcellular organelles, in a variety of cell types, including capillary endothelial and vascular smooth muscle cells (SMCs), renal (podocytes, tubular cells, glomerular endothelial, mesangial and interstitial cells), cardiac (cardiomyocytes and fibroblasts) and nerve cells (neurons, Schwann cells, etc.). The primary disease process starts in infancy, or even as early as in the fetal stage of development. However, in contrast to many other lysosomal storage diseases, most patients remain clinically asymptomatic or mildly symptomatic during the first years of life. First symptoms typically arise in childhood or adolescence and include, among others, neuropathic pain, angiokeratoma and cornea verticillata. Serious complications developing in adulthood include progressive renal insufficiency, cardiac complications (arrhythmia, hypertrophic cardiomyopathy) and/or cerebrovascular complications (e.g. early stroke).


Enzyme replacement therapy Fabry disease Globotriaosylceramide Globotriaosylsphingosine Lysosomal disease Painful neuropathy Stroke 


  1. 1.
    Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic bases of inherited disease. 8th ed. New York: MacGraw-Hill; 2001. p. 3733–74.Google Scholar
  2. 2.
    Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Desnick RJ. Prenatal diagnosis of Fabry disease. Prenat Diagn. 2007;27(8):693–4.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Thurberg BL, Politei JM. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. Hum Pathol. 2012;43(4):610–4.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human α-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP, Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112–28.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769–75.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop DF, Desnick RJ, Suzuki Y. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47(5):784–9.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease—recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509–14.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003;80(3):307–14.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kobayashi M, Ohashi T, Fukuda T, Yanagisawa T, Inomata T, Nagaoka T, Kitagawa T, Eto Y, Ida H, Kusano E. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene. Mol Genet Metab. 2012;107(4):711–5.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31–40.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, Bembi B, Cazzorla C, Rubert L, Zordan R, Desnick RJ, Burlina AP. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41(2):209–19.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Chien YH, Lee NC, Chiang SC, Desnick RJ, Hwu WL. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns—superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med. 2012;18:780–4.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450–6.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Rigoldi M, Concolino D, Morrone A, Pieruzzi F, Ravaglia R, Furlan F, Santus F, Strisciuglio P, Torti G, Parini R. Intrafamilial phenotypic variability in four families with Anderson-Fabry disease. Clin Genet. 2014;86(3):258–63.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, Kaneski CR. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, Shayman JA. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int. 2014;86(1):58–66.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26(6):1797–802.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab. 2010;100(3):257–61.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105(8):2812–7.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, Kanekura T, Sakuraba H. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem Biophys Res Commun. 2010;399(4):716–20.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Weidemann F, Sanchez-Niño MD, Politei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64(5):550–5.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95(1):86–92.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, Møller AT, Hilz MJ. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Uçeyler N, Magg B, Thomas P, Wiedmann S, Heuschmann P, Sommer C. A comprehensive Fabry-related pain questionnaire for adult patients. Pain. 2014;155(11):2301–5.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kolodny EH, Pastores GM. Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol. 2002;13(Suppl 2):S150–3.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Rahman AN, Simeone FA, Hackel DB, Hall PW, Hirsch EZ, Harris JW. Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis). Trans Assoc Am Phys. 1971;74:366–77.Google Scholar
  32. 32.
    Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002;11(2):127–33.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Watt T, Burlina AP, Cazzorla C, Schönfeld D, Banikazemi M, Hopkin RJ, Martins AM, Sims K, Beitner-Johnson D, O’Brien F, Feldt-Rasmussen U. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010;12(11):703–12.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Marchesoni CL, Roa N, Pardal AM, Neumann P, Cáceres G, Martínez P, Kisinovsky I, Bianchi S, Tarabuso AL, Reisin RC. Misdiagnosis in Fabry disease. J Pediatr. 2010;156(5):828–31.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184–92.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol. 2002;19(6):575–86.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Biegstraaten M, Hollak CE, Bakkers M, Faber CG, Aerts JM, van Schaik IN. Small fiber neuropathy in Fabry disease. Mol Genet Metab. 2012;106(2):135–41.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Politei JM, Durand C, Schenone AB. Small fiber neuropathy in Fabry disease: a review of pathophysiology and treatment. J Inborn Err Metab Screening. 2016;4:1–53.Google Scholar
  39. 39.
    Üçeyler N, Kahn AK, Kramer D, Zeller D, Casanova-Molla J, Wanner C, Weidemann F, Katsarava Z, Sommer C. Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study. BMC Neurol. 2013;13:47.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Schiffmann R, Scott LJ. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl. 2002;91(439):48–52.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000;84(2–3):361–5.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32(5):498–502.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Hilz MJ, Koehn J, Kolodny EH, Brys M, Moeller S, Stemper B. Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy. J Hypertens. 2011;29(12):2387–94.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol. 1992;31(4):409–15.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Germain DP, Atanasiu OI, Akrout-Marouene J, Benistan K. Raynaud’s phenomenon associated with Fabry disease. J Inherit Metab Dis. 2015;38:367–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Møller AT, Bach FW, Feldt-Rasmussen U, Rasmussen AK, Hasholt L, Sommer C, Kølvraa S, Jensen TS. Autonomic skin responses in females with Fabry disease. J Peripher Nerv Syst. 2009;14(3):159–64.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Stemper B, Hilz MJ. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol. 2003;250(8):970–6.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Buda P, Książyk J, Tylki-Szymanska A. Gastroenterological complications of Anderson-Fabry disease. Curr Pharm Des. 2013;19(33):6009–13.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, Fujita T, Ueda K. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci. 1998;18(2):109–17.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Lidove O, Ramaswami U, Jaussaud R, Barbey F, Maisonobe T, Caillaud C, Beck M, Sunder-Plassmann G, Linhart A, Mehta A, FOS European Investigators. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract. 2006;60(9):1053–9.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Bierer G, Kamangar N, Balfe D, Wilcox WR, Mosenifar Z. Cardiopulmonary exercise testing in Fabry disease. Respiration. 2005;72(5):504–11.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Biegstraaten M, van Schaik IN, Wieling W, Wijburg FA, Hollak CE. Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC Neurol. 2010;10:38.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Lim SN, Huang CC, Kuo HC, Hsieh YC, Chu CC. Subtle changes in cutaneous nerves and sural nerve biopsy in a patient With Fabry’s disease. J Clin Neuromuscul Dis. 2005;7(1):19–24.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Gayathri N, Yasha TC, Kanjalkar M, Agarwal S, Sagar BK, Santosh V, Shankar SK. Fabry’s disease: an ultrastructural study of nerve biopsy. Ann Indian Acad Neurol. 2008;11(3):182–4.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Toyooka K, Said G. Nerve biopsy findings in hemizygous and heterozygous patients with Fabry’s disease. J Neurol. 1997;244(7):464–8.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kahn P. Anderson-Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry. 1973;36(6):1053–62.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Üçeyler N, He L, Schönfeld D, Kahn AK, Reiners K, Hilz MJ, Breunig F, Sommer C. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerv Syst. 2011;16(4):304–14.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Liguori R, Di Stasi V, Bugiardini E, Mignani R, Burlina A, Borsini W, Baruzzi A, Montagna P, Donadio V. Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve. 2010;41:409–12.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Godel T, Bäumer P, Pham M, Köhn A, Muschol N, Kronlage M, Kollmer J, Heiland S, Bendszus M, Mautner VF. Human dorsal root ganglion in vivo morphometry and perfusion in Fabry painful neuropathy. Neurology. 2017;89:1274–82.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31(1):67–76.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Choi L, Vernon J, Kopach O, Minett MS, Mills K, Clayton PT, Meert T, Wood JN. The Fabry disease-associated lipid lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett. 2015;594:163–8.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Tomé FM, Fardeau M, Lenoir G. Ultrastructure of muscle and sensory nerve in Fabry’s disease. Acta Neuropathol. 1977;38(3):187–94.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Lakomá J, Rimondini R, Ferrer Montiel A, Donadio V, Liguori R, Caprini M. Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model. Mol Pain. 2016;12:1–16. pii: 1744806916663729.CrossRefGoogle Scholar
  64. 64.
    Laaksonen SM, Röyttä M, Jääskeläinen SK, Kantola I, Penttinen M, Falck B. Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol. 2008;119(6):1365–72.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Ghali J, Murugasu A, Day T, Nicholls K. Carpal tunnel syndrome in Fabry disease. JIMD Rep. 2012;2:17–23.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Scott LJ, Griffin JW, Luciano C, Barton NW, Banerjee T, Crawford T, McArthur JC, Tournay A, Schiffmann R. Quantitative analysis of epidermal innervation in Fabry disease. Neurology. 1999;52(6):1249–54.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Tavakoli M, Marshall A, Thompson L, Kenny M, Waldek S, Efron N, Malik RA. Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease. Muscle Nerve. 2009;40(6):976–84.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Politei J, Thurberg BL, Wallace E, Warnock D, Serebrinsky G, Durand C, Schenone AB. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin Genet. 2016;89(1):5–9.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210–4.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol. 2005;33:164–8.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Franceschetti AT. Fabry disease: ocular manifestations. Birth Defects Orig Artic Ser. 1976;12(3):195–208.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Falke K, Buttner A, Schittkowski M, Stachs O, Kraak R, Zhivov A, Rolfs A, Guthoff R. The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study. Graefes Arch Clin Exp Ophthalmol. 2009;247:523–34.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Sivley MD. Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci. 2013;90(2):e63–78.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Sher NA, Reiff W, Letson RD, Desnick RJ. Central retinal artery occlusion complicating Fabry’s disease. Arch Ophthalmol. 1978;96(5):815–7.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Andersen MV, Dahl H, Fledelius H, Nielsen NV. Central retinal artery occlusion in a patient with Fabry’s disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol (Copenh). 1994;72(5):635–8.CrossRefGoogle Scholar
  76. 76.
    Mitchell KT, Bradley JC, Gilmore LS, Meyerrose GE. Sequential bilateral central retinal artery occlusions in a female carrier of Fabry disease. Clin Exp Ophthalmol. 2009;37(7):748–50.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Larralde M, Boggio P, Amartino H, Chamoles N. Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. Arch Dermatol. 2004;140(12):1440–6.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Pintos Morell G. Fabry’s disease: diagnosis in the pediatric age group. An Esp Pediatr. 2002;57(1):45–50.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Jansen T, Graue N, Dissemond J, Hillen U, Hentschke M, Grabbe S. Telangiectasias on the neck as a presenting cutaneous sign of Fabry disease. J Dermatol. 2006;33(9):652–4.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, Ramaswami U, Parini R, Sunder-Plassman G, Beck M, Mehta AB, FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet. 2002;3:10.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Ciceran A, De Maio S. Cochleovestibular Manifestations in Fabry Disease. J Inborn Errors Met Screening. 2016;4:1–4.Google Scholar
  83. 83.
    Malinvaud D, Avan P, Germain DP, Benistan K, Bonfils P. The cochlea in Fabry disease: a sensorineural hearing loss model of vascular origin? Rev Med Interne. 2006;27(7):527–31.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Schachern PA, Shea DA, Paparella MM, Yoon TH. Otologic histopathology of Fabry’s disease. Ann Otol Rhinol Laryngol. 1989;98(5 Pt 1):359–63.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Ries M, Kim HJ, Zalewski CK, Mastroianni MA, Moore DF, Brady RO, Dambrosia JM, Schiffmann R, Brewer CC. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain. 2007;130:143–50.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Palla A, Hegemann S, Widmer U, Straumann D. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol. 2007;254:1433–42.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D, Zeman J, Ledvinova J, Poupetova H, Elleder M, Aschermann M. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139:1101–8.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40:1668–74.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet. 2003;63:46–52.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96:842–6.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592–601.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Acharya D, Robertson P, Kay GN, Jackson L, Warnock DG, Plumb VJ, Tallaj JA. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol. 2012;35(12):738–40.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Sivaloganathan S. Fabry’s disease—a rare cause of sudden death. Med Sci Law. 1992;32(3):263–6.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Carter N, Milroy CM, Shepherd RT. Sudden death in elderly women with Fabry’s disease. Am J Forensic Med Pathol. 1995;16(1):21–6.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abiose A. Cardiovascular events in patients with Fabry disease natural history data from the Fabry Registry. J Am Coll Cardiol. 2011;57(9):1093–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    O’Mahony C, Coats C, Cardona M, Garcia A, Calcagnino M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. 2011;13(12):1781–8.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holzmeister J, Lüscher TF, Jenni R, Duru F. Electrocardiographic changes in early recognition of Fabry disease. Heart. 2011;97(6):485–90.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry’s disease. N Engl J Med. 2003;348(12):1186–7.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J. 1977;93(6):699–705.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539–48.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51(1):50–9.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110(9):1047–53.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC, Janatuinen T, Raitakari OT, Knuuti J, Penttinen M, Viikari J, Nuutila P. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006;29(1):112–8.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790–6.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Najafian B, Mauer M, Hopkin RJ, Svarstad E. Renal complications of Fabry disease in children. Pediatr Nephrol. 2013;28(5):679–87.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Najafian B, Svarstad E, Bostad L, Gubler MC, Tøndel C, Whitley C, Mauer M. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011;79(6):663–70.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Waldek S, Feriozzi S. Fabry nephropathy: a review—how can we optimize the management of Fabry nephropathy? BMC Nephrol. 2014;15:72.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol. 2002;13(Suppl 2):S139–43.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. Epub 2018 Feb 28.
  110. 110.
    Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, Paulero M, Rengel T, Aráoz A, Forrester M, Lombi F, Pomeranz V, Iriarte R, Young P, Muryan A, Zotta E. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J Nephrol. 2016;29(6):791–7.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Burlina A, Politei J. The central nervous system involvement in Fabry disease: a review. J Inborn Errors Metab Screening. 2016;4:1–7.CrossRefGoogle Scholar
  112. 112.
    Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009;40:788–94.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Chang YH, Hwang SK. A case of cerebral aneurysmal subarachnoid hemorrhage in Fabry’s disease. J Korean Neurosurg Soc. 2013;53(3):187–9.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Cormican MT, Paschalis T, Viers A, Alleyne CH Jr. Unusual case of subarachnoid haemorrhage in patient with Fabry’s disease: case report and literature review. BMJ Case Rep. 2012.
  115. 115.
    Kono Y, Wakabayashi T, Kobayashi M, Ohashi T, Eto Y, Ida H, Iguchi Y. J Stroke Cerebrovasc Dis. 2016;25:1320–5.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, Silva FA, Tuna A, Rodrigues M, Ferreira C, Pinto AA, Leitao A, Gabriel JP, Calado S, Oliveira JP, Ferro JM, PORTuguese Young STROKE. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study—screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431–6.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, Politei J, Manara R, Burlina A. cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015;46:302–13.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007;30(6):943–51.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry’s disease. Dement Geriatr Cogn Disord. 1997;8(4):252–7.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366(9499):1794–6.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Poli L, Zedde M, Zini A, Del Sette M, Lodigiani C, Spalloni A, Di Lisi F, Toriello A, Piras V, Stilo C, Tomelleri G, Tancredi L, Paciaroni M, Silvestrelli G, Adami A, Costa P, Morotti A, De Giuli V, Caria F, Gamba M, Malferrari G, Simone AM, Musolino R, Giorli E, Banfi E, Marcheselli S, Rasura M, Pugliese N, Melis M, Bovi P, Padovani A, Burlina A, Pezzini A, Italian Project on Stroke in Young Adults (IPSYS) Investigators. Eur J Neurol. 2017;24:e12–4.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Lanthier S, Saposnik G, Lebovic G, Pope K, Selchen D, Moore DF, Canadian Fabry Stroke Screening Initiative Study Group. Stroke. 2017;48:1766–72.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007;30(1):68–78.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore). 2005;84(5):261–8.CrossRefGoogle Scholar
  125. 125.
    Mehta A, Ginsberg L, FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl. 2005;94(447):24–7.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Grewal RP. Stroke in Fabry’s disease. J Neurol. 1994;241(3):153–6.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65(4):600–2.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Ginsberg L, Manara R, Valentine AR, Kendall B, Burlina AP. Magnetic resonance imaging changes in Fabry disease. Acta Paediatr Suppl. 2006;95:57–62.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci. 2011;305(1–2):41–4.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Rost NS, Cloonan L, Kanakis AS, Fitzpatrick KM, Azzariti DR, Clarke V, Lourenço CM, Germain DP, Politei JM, Homola GA, Sommer C, Üçeyler N, Sims KB. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology. 2016;86:1880–6.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Underhill HR, Golden-Grant K, Garrett LT, Uhrich S, Zielinski BA, Scott CR. Detecting the effects of Fabry disease in the adult human brain with diffusion tensor imaging and fast bound-pool fraction imaging. J Magn Reson Imaging. 2015;42:1611–22.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Lou HOC, Reske-Nielsen E. The central nervous system in Fabry’s disease. A clinical, pathological, and biochemical investigation. Arch Neurol. 1971;25:351–9.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, Steinmann B, Burnier M, Palecek T, Bultas J, Hayoz D. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006;26(4):839–44.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Park JL, Whitesall SE, D’Alecy LG, Shu L, Shayman J. Vascular dysfunction in the alphagalactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol. 2008;35:1156–63.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, McCarron R, Schiffmann R. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47(2):229–33.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004;251(5):564–70.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, Mignani R, Oarini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79:1249–54.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol. 2002;18(2):4.CrossRefGoogle Scholar
  139. 139.
    Politei JM, Capizzano AA. Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist. 2006;12(2):103–5.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Tagliavini F, Pietrini V, Gemignani F, Lechi A, Pallini R, Federico A. Anderson-Fabry disease: neuropathological and neurochemicl investigation. Acta Neuropathol. 1982;56:93–8.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol. 1988;23(5):505–9.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Okeda R, Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology. 2008;28(5):532–40.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Takashima S, Matsui A, Fujii Y, Nakamura H. Clinicopathological differences between juvenile and late infantile metachromatic leukodystrophy. Brain Dev. 1981;3(4):365–74.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Kornfeld M. Neuropathology of chronic GM2 gangliosidosis due to hexosaminidase A deficiency. Clin Neuropathol. 2008;27(5):302–8.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Prüss H, Bohner G, Zschenderlein R. Paroxysmal vertigo as the presenting symptom of Fabry disease. Neurology. 2006;66(2):249.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Politei J, Schenone A, Burlina A, Blanco M, Lescano S, Szlago M, Cabrera G. Vertebrobasilar dolichoectasia in Fabry disease: the earliest marker of neurovascular involvement? J Inborn Errors Metab Screening. 2014;2:1–6.CrossRefGoogle Scholar
  147. 147.
    Ubogu E, Zaidat O. Vertebrobasilar dolichoectasia diagnosed by magnetic resonance angiography and risk of stroke and death: a cohort study. J Neurol Neurosurg Psychiatry. 2004;75(1):22–6.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Kumral E, Kisabay A, Ataç C, Kaya C, Calli C. The mechanism of ischemia stroke in patients with dolichoectatic basilar artery. Eur J Neurol. 2005;12(6):437–44.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Pico F, Labreuche J, Seilhean D, Duyckaerts C, Hauw JJ, Amarenco P. Association of small vessel disease with dilatative arteriopathy of the brain: neuropathologic evidence. Stroke. 2007;38(4):1197–202.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Kwon HM, Kim J, Lim J-S, Park JH, Lee SH, Lee YS. Basilar artery dolichoectasia is associated with paramedian pontine infarction. Cerebrovasc Dis. 2009;27(2):114–8.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Pico F, Labreuche J, Touboul PJ, Leys D, Amarenco P. Intracranial arterial dolichoectasia and small-vessel disease in stroke patients. Ann Neurol. 2005;57(4):472–9.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Thijs V, Grittner U, Fazekas F, McCabe DJH, Giese A-K, Kessler C, Martus P, Norrving B, Ringelstein EB, Schmidt R, Tanislav C, Putaala J, Tatlisumak T, von Sarnowski B, Rolfs A, Enzinger C, Stroke in Fabry (SIFAP1) Investigators. Dolichoectasia and small vessel diseases in young patients with transient ischemic attack and stroke. Stroke. 2017;48(9):2361–7.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Arterial remodelling in Fabry disease. Acta Paediatr Suppl. 2002;91(439):62–6.PubMedCrossRefPubMedCentralGoogle Scholar
  154. 154.
    Barbey F, Brakch N, Linhart A, et al. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl. 2006;95(451):63–8.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Sho E, Sho M, Singh TM, Nanjo H, Komatsu M, Xu C, Masuda H, Zarins CK. Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol. 2002;73(2):142–53.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol. 2000;20(12):E120–6.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med. 2006;259(4):381–92.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Shah JS, Hughes DA, Tayebjee MH, MacFadyen RJ, Mehta AB, Elliott PM. Extracellular matrix turnover and disease severity in Anderson-Fabry disease. J Inherit Metab Dis. 2007;30(1):88–95.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40(1):8–17.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Fellgiebel A, Keller I, Marin D, Müller MJ, Schermuly I, Yakushev I, Albrecht J, Bellhäuser H, Kinateder M, Beck M, Stoeter P. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009;72(1):63–8.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Manara R, Carlier RY, Righetto S, Citton V, Locatelli G, Colas F, Ermani M, Germain DP, Burlina A. Basilar artery changes in Fabry disease. Am J Neuroradiol. 2017;38:531–6.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Masey DN, Cosh JA. Basilar artery aneurysm and Anderson-Fabry disease. J Neurol Neurosurg Psychiatry. 1980;43:85–7.CrossRefGoogle Scholar
  163. 163.
    Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003;24(6):1096–101.PubMedPubMedCentralGoogle Scholar
  164. 164.
    Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. Am J Neuroradiol. 2003;24:916–21.PubMedPubMedCentralGoogle Scholar
  165. 165.
    Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina A, Lidove O. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol. 2008;255(5):738–44.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Burlina AP, Politei J, Cinque S, Soliani A, Carlier RY, Germain DP, Manara R. The pulvinar sign in Fabry patients: the first report in female patients. J Neurol. 2012;259(6):1227–8.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Cocozza S, Russo C, Pisani A, Olivo G, Riccio E, Cervo A, Pontillo G, Feriozzi S, Veroux M, Battaglia Y, Concolino D, Pieruzzi F, Mignani R, Borrelli P, Imbriaco M, Brunetti A, Tedeschi E, Palma G. Redefining the pulvinar sign in Fabry disease. Am J Neuroradiol. 2017;38(12):2264–9.PubMedCrossRefPubMedCentralGoogle Scholar
  168. 168.
    Lee HJ, Hung SC, Hsu TR, Ko SC, Chui-Mei T, Huang CC, Niu DM, Lin CP. Brain MR imaging findings of cardiac-type Fabry disease with an IVS4+919G>A mutation. Am J Neuroradiol. 2016;37:1044–9.PubMedCrossRefPubMedCentralGoogle Scholar
  169. 169.
    Milhorat TH, Chou MW, Trinidad EM, Kula RW, Mandell M, Wolpert C, Speer MC. Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients. Neurosurgery. 1999;44(5):1005–17.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Germain DP, Benistan K, Halimi P. Chiari type I malformation in four unrelated patients affected with Fabry disease. Eur J Med Genet. 2006;49(5):419–25.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol. 2008;51(21):2082.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotype of Fabry disease. J Med Genet. 2015;52:262–8.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Polo G, Burlina AP, Kolamunnage TB, Zampieri M, Dionisi-Vici C, Strisciuglio P, Zaninotto M, Plebani M, Burlina AB. Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS/MS. Clin Chem Lab Med. 2017;55:403–14.PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Arends M, Wijburg FA, Wanner C, Vaz FM, van Kullenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121:157–61.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 2006;118(3):924–32.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96(1):122–7.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, Germain DP. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152(4):563–70.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard Lund A. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432–8.PubMedCrossRefPubMedCentralGoogle Scholar
  179. 179.
    Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75(1):65–74.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, A delta-, and A beta-nerve fibers in Fabry neuropathy. Neurology. 2004;62(7):1066–72.PubMedCrossRefPubMedCentralGoogle Scholar
  181. 181.
    Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37(3):341–52.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis. 2014;38:448–56.PubMedCrossRefPubMedCentralGoogle Scholar
  183. 183.
    Jardim LB, Aesse F, Vedolin LM, Pitta-Pinheiro C, Marconato J, Burin MG, Cecchin C, Netto CB, Matte US, Pereira F, Kalakun L, Giugliani R. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr. 2006;64(3B):711–7.PubMedCrossRefPubMedCentralGoogle Scholar
  184. 184.
    El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One. 2017;12(3):e0173358.PubMedPubMedCentralCrossRefGoogle Scholar
  185. 185.
    Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24(1):137–48.PubMedCrossRefPubMedCentralGoogle Scholar
  186. 186.
    Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353–8.PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet. 2016;53:495–502.PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenço CM, Banikazemi M, Charrow J, Dasouki M, Fineglod D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry’s disease with pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545–55.PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Politei JM, Bouhassira D, Germain DP, Goizet C, Guerrero-Sola A, Hilz MJ, Hutton EJ, Karaa A, Liguori R, Üçeyler N, Zeltzer LK, Burlina A. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568–76.PubMedPubMedCentralCrossRefGoogle Scholar
  190. 190.
    Politei JM. Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis. 2009;32(4):481–7.PubMedCrossRefPubMedCentralGoogle Scholar
  191. 191.
    Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C, Conference Participants. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91(2):284–93.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Alessandro P. Burlina
    • 1
  • Juan Politei
    • 2
  1. 1.Neurological Unit, St Bassiano HospitalBassano del GrappaItaly
  2. 2.Laboratorio de Neuroquímica Dr. N. A. Chamoles, Fundación para el Estudio de las Enfermedades Neurometabólicas (FESEN)Buenos AiresArgentina

Personalised recommendations